Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's the story here? Chart looks great, but seemingly all sells today since the morning bell and morning spike....
NEW YORK, June 15, 2020 THERAPEUTICS' SCIENTIFIC ADVISORY BOARD MEMBER AND INVENTOR OF LICENSED NOVEL PEPTIDE COVID-19 THERAPEUTIC, DR. MICHAEL PETERS, PUBLISHES WHITE PAPER
NEW YORK, June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering, has published a white paper detailing his mappings of the COVID-19 virus and its spike protein.
(PRNewsfoto/Hoth Therapeutics Inc.)
Hoth has licensed technology and intellectual property exclusively from VCU for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission.
The spike in protein plays an important role in attaching to human cells and infecting the body. Researchers at VCU have developed at novel peptide that binds with extremely high affinity to SD1 segment of the SARS-CoV-2 spike protein mimicking its attachment to ACE2. This high binding affinity helps block the spike protein from attaching to the ACE2 surface receptor, thus limiting the transmission of the virus.
The SARS-Cov-2 virion responsible for the current world-wide pandemic COVID-19 has a characteristic Spike protein (S) on its surface that embellishes both a prefusion state and fusion state. The prefusion Spike protein (S) is a large trimeric protein where each protomer may be in a so-called Up state or Down state, depending on the configuration of its receptor binding domain (RBD). The Up state is believed to allow binding of the virion to ACE-2 receptors on human epithelial cells, whereas the Down state is believed to be relatively inactive or reduced in its binding behavior.
Currently, Peters is utilizing supercomputers as part of COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system that scientists can use to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.
HOTH THERAPEUTICS ENTERS INTO EXPANDED SPONSORED RESEARCH AGREEMENT WITH THE GEORGE WASHINGTON UNIVERSITY FOR DERMATOLOGY TREATMENT CANDIDATE WEG232
WEG232 IS A TOPICAL TREATMENT WITH SPECIFIC SUBSTANCE P-RECEPTOR INHIBITOR FOR ERLOTINIB-INDUCED FACIAL DERMATITIS AND HAIR LOSS IN CANCER PATIENTS
NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.
(PRNewsfoto/Hoth Therapeutics Inc.)
The company has increased its commitment to further the science behind this therapeutic with Dr. William Wegliki's lab at GW. Hoth intends to request a Pre-IND meeting with the FDA by year-end.
Hoth continues to develop topical WEG232 formulation for treatment of mild to moderate (grades 1-3) rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. A recent research study suggested the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity.
Future studies will include:
Determining the optimal treatment or pretreatment time of application and the weekly number of applications, eg. 2 or 3/week, of WEG232 to prevent the occurrence of the anticipated skin rash/hair loss.
*** breakout !
Your very welcome...yes...
Thx for this one Georgie...you still bullish on rbnw?
AIKI...89...P/M...
georgie18 Saturday, 06/06/20 06:23:21 AM
Re: Citrati post# 7743 0
Post #
7744
of 7769
AIKI...73...Consolidation Channel Breakout setting up here on the Bollie Squeeze...as the Psar is ready to flip to a Bullish Buy Position...
As of May 13, 2020, there were 34,920,219 shares of the Company’s common stock issued and outstanding.
https://www.otcmarkets.com/filing/html?id=14148986&guid=JvaHUnzRuvrmGth
Chart...http://schrts.co/nxCbhCuz
Been accumulating AIKI for months also collected a nice Divvy of HOTH shares currently priced at $2.80...
Wow...thank you ,view.
I've been away at least 4 yrs. I held spex when it was run by Rockstar Holdings, I believe was the name.Lolol
http://schrts.co/inQJSiRq It's time for AIKI to come up with explosive news and go to $5 plus again .
People are watching silently. AIKI is now SPEX, name changed.
It looks like you have to do some DD to catch up. HOTH is a subsidiary of AIKI and some good updates.
https://aikidopharma.com/
https://www.otcmarkets.com/stock/AIKI/disclosure
Good luck!
SPEX changed ticker name to AIKI.
is spex defunct?
I was searching it and this Aiki ticker came up.
Just trying to get an idea of what's going on with this ticker these days.
Thanks for any help !
ghost.
Hey view...any upcoming catalysts here?
Seems way undervalued and very quiet on the message board as well. What gives ?
Hey Smart, just came across this while looking for spex ....held spex about 4-5 years ago. Checking in on it and seen your post. Is this litigation against spex management?
Is this worth getting in at this time ? I wasn't aware of the ticker change until I searched spex and Aiki pharm came up lolol.
Thanks for your time.
ghost.
Shes gonna blow !
WEG232 is a topical treatment with specific substance P-receptor inhibitor for Erlotinib-induced facial dermatitis and hair loss in cancer patients
NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.
The company has increased its commitment to further the science behind this therapeutic with Dr. William Wegliki's lab at GW. Hoth intends to request a Pre-IND meeting with the FDA by year-end.
Hoth continues to develop topical WEG232 formulation for treatment of mild to moderate (grades 1-3) rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. A recent research study suggested the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity.
Future studies will include:
Determining the optimal treatment or pretreatment time of application and the weekly number of applications, eg. 2 or 3/week, of WEG232 to prevent the occurrence of the anticipated skin rash/hair loss.
Determine at the facial skin level if differentially effective topical applications correlate with the extent of suppressed SP-mediated neurogenic inflammation.
Determine any impact the topical WEG232 application may have on the indicators of systemic neurogenic inflammation and oxidative stress.
"We are pleased to broaden our relationship with the George Washington University as we continue to make great strides in bringing a much needed therapeutic to patients struggling with the many side effects of chemo and immunotherapy," stated Mr. Robb Knie, CEO of Hoth Therapeutics.
Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University for Dermatology Treatment Candidate WEG232
$5 is not unrealistic, it can get there in a few days with a real good news. IMO.
AIKI will start moving like crazy once COVID-19 calms down a little. IMO.
That was good news. It usually gives back some after gaining, they are offering to sell stock to raise money also.
So is this bad news for us? Because we are down 4 cents premarket
NEWS. Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions
The patent will be used in compounds to treat in vivo anti-cancer activity and in vitro for treating dermatology conditions
NEW YORK, June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application Number: 15/528,317 related to "13-Cis-RAMBA Retinamides that Degrade MNKs for Treating Cancer".
The Notice of Allowance concludes the substantive examination of the US Patent Application by the USPTO and will result in the issuance of a US patent after remaining administrative processes are completed. Hoth Therapeutics continues to strengthen the company's intellectual property portfolio surrounding new generation therapies treating various diseases.
"We are pleased to receive allowance of additional claims from the USPTO, which marks a critical step in bolstering our intellectual property portfolio protecting novel therapeutics designed to target dermatological disorders," stated Mr. Robb Knie, CEO of Hoth Therapeutics. "This patent regarding several methods will be critical as we move compounds to treat in vivo anti-cancer activity and in vitro for treating dermatology conditions forward."
Researchers at UMB discovered novel retinamide RAMBAs and validated their therapeutic utility in animal models of breast and prostate cancer. RAMBAs inhibit the cellular enzyme that metabolizes all-trans retinoic acid (ATRA), which actively directs cells to mature in a controlled manner to ensure normal growth. In addition to enhancing the beneficial effects of ATRA, the mechanism of action for these RAMBAs has been shown to involve degradation of Mnk 1/2 and suppression of the oncogenic eIF4E pathway. For potential use in treating dermatological conditions, UMB researchers obtained promising early results demonstrating that lead retinamide RAMBAs have equal or superior effects over approved retinoids (ATRA and 13-CRA) to inhibit proliferation of normal human adult keratinocytes and sebocytes, and antikeratinizing effects in reconstructed human epidermis. Initial toxicity profiles for a panel of RAMBAs [Njar et al., 2006] also showed good indications for safe therapeutic use.
https://www.otcmarkets.com/filing/html?id=14205853&guid=i2UFUa8Btc7zVyh
So the $5 is coming soon with those licenses?
AIKI~~loks like NEWSSSSSSSSSSSS,moving fast up,.7977
It's about time we see $5's again.
Some good news should be popping anytime soon?
Thanks for the extra tip. That is a nice set up.
AIKI...73...Consolidation Channel Breakout setting up here on the Bollie Squeeze...as the Psar is ready to flip to a Bullish Buy Position...
As of May 13, 2020, there were 34,920,219 shares of the Company’s common stock issued and outstanding.
https://www.otcmarkets.com/filing/html?id=14148986&guid=JvaHUnzRuvrmGth
Chart...http://schrts.co/nxCbhCuz
Been accumulating AIKI for months also collected a nice Divvy of HOTH shares currently priced at $2.80...
I have just sent requests to brokers to disclose the identity of the market makers they rout my orders to. I have not been receiving these unmasked identities despite the SEC Rules so providing. Once, I get that information, we will submit our complaints against these Criminals: AIKI, AFH, PRTY, SNDL.
Akh... We see those numbers all day 12 hours a day! LOL. AIKI needs to move already!
$AIKI .80 ...... moving
Your very welcome...
Thank you...im good with that
My sell points are based on candlestick patterns so they may not be your sell points...I will post accordingly...
My achilles heel is not knowing when to buy a stock. Good at that. Its knowing when to sell. That's why I follow you. Please keep giving your input on getting out. I realize its only your opinion but it helps. Thx
AIKI...73...adding on the bollie squeeze...
AIKI~~.77 going PM,NEWS???
And why? I was in the run for that crazy 3 or 4 days watching me cook that Friday after hours insane.
AIKI gonna spike to $3.00-5.00 ,500%%%% ,waiting here
Followers
|
156
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |